Agenus Inc.

11/07/2024 | Press release | Distributed by Public on 11/07/2024 12:02

Fc Enhanced Anti CTLA 4 Antibody, Botensilimab, Enhances the Efficacy of Multiple Therapeutic Modalities in Immunotherapy Refractory Tumor Models